Technology | March 27, 2012

FDA Clears GE Healthcare’s New Class of Angiography Systems

Class offers fixed system image quality and features with versatility of a mobile C-arm

The GE Healthcare Discovery IGS 730 angiography imaging system.

March 26, 2012 – GE Healthcare unveiled two recently U.S. Food and Drug Administration (FDA)-cleared angiography systems offering mobility and advanced imaging for interventional cardiology at the American College of Cardiology's (ACC) 61st Annual Scientific Session in Chicago this week. 

Specifically, GE highlighted its recently FDA-cleared Discovery IGS 730 system, the first interventional X-ray system designed to capture the advantages of both floor- and ceiling-mounted systems, and the mobility of a mobile C-arm. Initially introduced last fall during RSNA 2011, the Discovery system was designed to address the trade-off departments have historically needed to make between ceiling- and floor-mounted systems, eliminating the need to compromise on patient access and image quality. This laser-guided, motorized mobile gantry allows complete access to the patient and unlimited parking capability, while creating sterility for a flexible operating room (OR) environment. The unique gantry comes with a new wide bore design, which allows for steep angles, ease in 3-D acquisition, especially for large patients. 

GE will also introduce the FDA-approved Innova IGS 520/530 with the OR option to expand the use of its Innova imaging system in the hybrid OR setting. With specifically designed table and accessories, the Innova IGS 520/530 OR enables both transcatheter and open surgical procedures in one room.

GE also highlighted its Innova HeartVision solution to help support planning and guidance of structural heart procedures, especially trans-aortic valve replacement (TAVR) procedures. The HeartVision function fuses real time 2-D X-ray images and 3-D models, such as the 3-D cardiac model, from multiple modalities. It can be synchronized with electrocardiogram (ECG) gating and can help compensate for patient heart and respiratory motion throughout the procedure for quality treatment. Innova HeartVision can reduce procedure time and dose, and increase physician confidence by providing the visual tools to make challenging interventions more accessible.

“Interventional cardiology procedures are becoming increasingly complex, and now may be performed in a variety of settings in the hospital, including the operating room. GE Healthcare is revolutionizing cardiac imaging with solutions that adapt to a wider array of environments,” said Reaz Rasul, general manager, interventional cardiology, GE Healthcare - detection and guidance solutions. “With the development of Discovery IGS 730 and Innova IGS 520/530 OR, we are arming physicians with solutions that combine cutting-edge imaging with greater versatility to meet more clinical needs.”

To see a video of the system in operation when it was first unveiled at RSNA 2011, click here.

For more information:

Related Content

Videos | Heart Valve Technology | March 15, 2018
Insights from the STS/ACC TVT Transcatheter Valve Registry, presented at the American College of Cardiology (ACC) 201
CoreValve TAVR System Shows Strong Long-Term Performance in Clinical Trials
News | Heart Valve Technology | March 12, 2018
Medtronic plc unveiled outcomes from the CoreValve U.S. Pivotal Extreme Risk Study and the real-world NOTION trial (...
The U.S. Food and Drug Administration expanded the approval of a heart valve to include a size small enough to be used in newborn pediatric patients to treat heart defects.
News | Heart Valve Technology | March 07, 2018
The U.S. Food and Drug Administration expanded the approval of a heart valve to include a size small enough to be used...
Videos | Heart Valve Technology | March 02, 2018
Sammy Elmariah, M.D., MPH, interventional structural heart disease, Massachusetts General Hospital, discusses the pro
Boston Scientific Projects 2019 Launch for Lotus Edge Aortic Valve System
News | Heart Valve Technology | February 23, 2018
February 23, 2018 — Boston Scientific announced In November 2017 a delay to timelines for commercialization of the Lo
Gate Bioprosthesis Used in Canada's First Transcatheter Valve Replacement for Tricuspid Regurgitation
News | Heart Valve Technology | February 22, 2018
NaviGate Cardiac Structures Inc. (NCSI)announced that on Feb. 2, 2018, its catheter-guided Gate valved-stent...
Edwards Lifesciences Centera self expanding transcatheter (TAVR) valve has been approved with CE mark for use in Europe.
Feature | Heart Valve Technology | February 15, 2018
February 15, 2018 — Edwards Lifesciences Corp.
Boston Scientific Enters Investment and Acquisition Option Agreement With Millipede
News | Heart Valve Technology | January 24, 2018
Boston Scientific Corp. announced it has closed an investment and entered into an acquisition option agreement with...
Edwards LifeSciences Recalls Sapien 3 Certitude Delivery System
News | Heart Valve Technology | January 11, 2018
The U.S. Food and Drug Administration (FDA) announced that Edwards LifeSciences is recalling its Certitude Delivery...
Videos | Heart Valve Technology | January 04, 2018
Adam Greenbaum, M.D., co-director, Center for Structural Heart Disease, Henry Ford Hospital, Detroit, explains how hi
Overlay Init